Edward Dompeling, MD; Constant P. van Schayck, PhD; Petrus M. van Grunsven, MD; Cees L. A. van Herwaarden, MD, PhD; Reinier Akkermans, MSc; Johan Molema, MD, PhD; Hans Folgering, MD, PhD; Chris van Weel, MD, PhD
Dompeling E, van Schayck CP, van Grunsven PM, van Herwaarden CLA, Akkermans R, Molema J, et al. Slowing the Deterioration of Asthma and Chronic Obstructive Pulmonary Disease Observed during Bronchodilator Therapy by Adding Inhaled Corticosteroids: A 4-Year Prospective Study. Ann Intern Med. 1993;118:770-778. doi: 10.7326/0003-4819-118-10-199305150-00003
Download citation file:
Published: Ann Intern Med. 1993;118(10):770-778.
To determine if deterioration in patients with asthma or chronic obstructive pulmonary disease (COPD) during bronchodilator therapy could be slowed by additional treatment with an inhaled corticosteroid.
A 4-year prospective study.
Twenty-nine general practices in the catchment area of the University of Nijmegen, Nijmegen, the Netherlands.
The study included 56 patients (28 with asthma and 28 with COPD) who showed an annual decrease in the forced expiratory volume in 1 second (FEV1) of at least 80 mL in combination with at least two exacerbations per year during bronchodilator therapy alone. Forty-eight patients completed the study.
During the first 2 years of treatment, patients received only bronchodilator therapy (salbutamol, 400 g, or ipratropium bromide, 40 g). During years 3 and 4, they received additional treatment with beclomethasone dipropionate, 400 g two times daily.
Prebronchodilator FEV1 increased 458 mL/y (95% CI, 233 to 683 mL/y) during the first 6 months of beclomethasone treatment; FEV1 then decreased 102 mL/y (CI, 57 to 147 mL/y) during months 7 to 24. The annual decline in FEV1 during beclomethasone treatment was less than the decline of 160 mL/y seen before beclomethasone therapy (difference, 58 mL/y; 95% CI, 2 to 87 mL/y). Only in patients with asthma did beclomethasone treatment improve bronchial hyper-responsiveness (assessed by determining the concentration of histamine that provoked a 20% decrease in FEV1 [PC20]) by 3.0 doubling doses per year (95% CI, 0.8 to 5.2 doses per year). Beclomethasone treatment was associated with improvement in peak expiratory flow rate, alleviation of symptoms, and a decrease in the number of exacerbations in both patient groups.
Adding beclomethasone, 800 g daily, slowed the unfavorable course of asthma or COPD seen with bronchodilator therapy alone. This effect was most evident in asthmatic patients.
Learn more about subscription options.
Register Now for a free account.
Pulmonary/Critical Care, Asthma, Chronic Obstructive Airway Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only